Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

Stock Information for Monopar Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.